Skip to main content

Fatty Acid Oxidation Disorders

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

OnKure Therapeutics
1 program
1
Low Dose REN001Phase 11 trial
Active Trials
NCT03833128Completed24Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OnKure TherapeuticsLow Dose REN001

Clinical Trials (1)

Total enrollment: 24 patients across 1 trials

A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders

Start: Apr 2019Est. completion: Mar 202224 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.